JP2024546436A5 - - Google Patents

Info

Publication number
JP2024546436A5
JP2024546436A5 JP2024527763A JP2024527763A JP2024546436A5 JP 2024546436 A5 JP2024546436 A5 JP 2024546436A5 JP 2024527763 A JP2024527763 A JP 2024527763A JP 2024527763 A JP2024527763 A JP 2024527763A JP 2024546436 A5 JP2024546436 A5 JP 2024546436A5
Authority
JP
Japan
Application number
JP2024527763A
Other languages
Japanese (ja)
Other versions
JPWO2023086864A5 (https=
JP2024546436A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079604 external-priority patent/WO2023086864A1/en
Publication of JP2024546436A publication Critical patent/JP2024546436A/ja
Publication of JP2024546436A5 publication Critical patent/JP2024546436A5/ja
Publication of JPWO2023086864A5 publication Critical patent/JPWO2023086864A5/ja
Pending legal-status Critical Current

Links

JP2024527763A 2021-11-12 2022-11-10 顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 Pending JP2024546436A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163278993P 2021-11-12 2021-11-12
US202163278882P 2021-11-12 2021-11-12
US63/278,993 2021-11-12
US63/278,882 2021-11-12
US202263312633P 2022-02-22 2022-02-22
US202263312617P 2022-02-22 2022-02-22
US63/312,633 2022-02-22
US63/312,617 2022-02-22
PCT/US2022/079604 WO2023086864A1 (en) 2021-11-12 2022-11-10 Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy

Publications (3)

Publication Number Publication Date
JP2024546436A JP2024546436A (ja) 2024-12-24
JP2024546436A5 true JP2024546436A5 (https=) 2025-11-18
JPWO2023086864A5 JPWO2023086864A5 (https=) 2025-11-18

Family

ID=86336621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527763A Pending JP2024546436A (ja) 2021-11-12 2022-11-10 顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Country Status (7)

Country Link
US (1) US20250025570A1 (https=)
EP (1) EP4429711A1 (https=)
JP (1) JP2024546436A (https=)
KR (1) KR20240099448A (https=)
CA (1) CA3234136A1 (https=)
IL (1) IL312170A (https=)
WO (1) WO2023086864A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025259503A1 (en) * 2024-06-12 2025-12-18 Dyne Therapeutics, Inc. Biomarkers for facioscapulohumeral muscular dystrophy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024535A2 (en) * 2010-08-18 2012-02-23 Fred Hutchinson Cancer Research Center Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
US20220193250A1 (en) * 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
AU2021206234A1 (en) * 2020-01-10 2022-09-01 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Similar Documents

Publication Publication Date Title
JP2024546436A5 (https=)
BR102023014872A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307044602S (https=)
CN307044215S (https=)
CN307049785S (https=)
CN307049360S (https=)
CN307048396S (https=)
CN307047622S (https=)
CN307047192S (https=)
CN307047044S (https=)
CN307046678S (https=)
CN307046430S (https=)
CN307046378S (https=)
CN307046025S (https=)
CN307045515S (https=)
BY13140U (https=)
CN307045446S (https=)
CN307045229S (https=)
CN307045100S (https=)
CN307044980S (https=)
BY13165U (https=)